U.S. Markets closed

Celgene’s Positive Drug Data Bolsters Bristol-Myers Deal, Analyst Says

Teresa Rivas

Robert W. Baird analyst Brian Skorney wrote that neither company is “a coveted prize, but both are better off together than apart.” Celgene stock is up on upbeat FDA actions.